研究業績

論文業績　2009～

2022

Original article

1. Chikamatsu M, Watanabe H, Shintani Y, Murata R, Miyahisa M, Nishinoiri A, Imafuku T, Takano M, Arimura N, Yamada K, Kamimura M, Mukai B, Satoh T, Maeda H, Maruyama T. Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease. J Control Release. 2023 Mar;355:42-53. doi: 10.1016/j.jconrel.2023.01.039.

2. Arimura N, Watanabe H, Kato H, Imafuku T, Nakano T, Sueyoshi M, Chikamatsu M, Tokumaru K, Nagasaki T, Maeda H, Tanaka M, Matsushita K, Maruyama T. Advanced Oxidation Protein Products Contribute to Chronic-Kidney-Disease-Induced Adipose Inflammation through Macrophage Activation. 2023 15(3), 179; https://doi.org/10.3390/toxins15030179

3. Nagase Y, Satoh T, Shigetome K, Tokumaru N, Matsumoto E, Yamada KD, Imafuku T, Watanabe H, Maruyama T, Ogata Y, Yoshida M, Saruwatari J, Oniki K. Serum Fatty Acid Composition Balance by Fuzzy C-Means Method in Individuals with or without Metabolic Dysfunction-Associated Fatty Liver Disease. 2023 Feb 4;15(4):809. doi: 10.3390/nu15040809.

4. Enoki Y, Nagai T, Hamamura Y, Osa S, Nakamura H, Taguchi K, Watanabe H, Maruyama T. Matsumoto K. The G protein-coupled receptor ligand apelin-13 ameliorates skeletal muscle atrophy induced by chronic kidney disease. J Cachexia Sarcopenia Muscle. 2023 Feb;14(1):553-564. doi: 10.1002/jcsm.13159. Epub 2022 Dec 23.

5. Matsumoto E, Oniki K, Ota-Kontani A, Seguchi Y, Sakamoto Y, Kaneko T, Imafuku T, Maeda H, Watanabe H, Maruyama T, Ogata Y, Yoshida M, Harada-Shiba M, Saruwatari J, Ogura M. Additive Effects of Drinking Habits and a Susceptible Genetic Polymorphism on Cholesterol Efflux Capacity. J Atheroscler Thromb. 2023 Jan 1;30(1):23-38. doi: 10.5551/jat.63277.

6. Maeda H, Ichimizu S, Watanabe H, Hamasaki K, Chikamatsu M, Murata R, Yumoto N, Seki T, Katsuki H, Otagiri M, Maruyama T. Cell-penetrating albumin enhances the sublingual delivery of antigens through macropinocytosis. Int J Biol Macromol. 2022 Nov 30;221:1439-1452. doi: 10.1016/j.ijbiomac.2022.09.132.

7. Takano M, Toda S, Watanabe H, Fujimura R, Nishida K, Bi J, Minayoshi Y, Miyahisa M, Maeda H, Maruyama T. Engineering of a Long-Acting Bone Morphogenetic Protein-7 by Fusion with Albumin for the Treatment of Renal Injury. 2022 Jun 24;14(7):1334. doi: 10.3390/pharmaceutics14071334.

8. Nagasaki T, Maeda H, Taguchi K, Yanagisawa H, Nishida K, Kobayashi K, Wada N, Noguchi I, Murata R, Sakai H, Kitagishi H, Saruwatari J, Watanabe H, Otagiri M, Maruyama T. A bioinspired carbon monoxide delivery system prevents acute kidney injury and the progression to chronic kidney disease. Redox Biol. 2022 Aug;54:102371. doi: 10.1016/j.redox.2022.102371.

9. Goto M, Kobira Y, Kaneko S, Arima H, Michihara A, Azuma K, Higashi T, Motoyama K, Watanabe H, Maruyama T, Kadowaki D, Otagiri M, Iohara D, Hirayama F, Anraku M. The Effects of Sacran, a Sulfated Polysaccharide, on Gut Microbiota Using Chronic Kidney Disease Model Rats. Biol Pharm Bull. 2022;45(5):576-582. doi: 10.1248/bpb.b21-00897.

Review

1. Watanabe H. Oxidized albumin: evaluation of oxidative stress as a marker for the progression of kidney disease. Biol Pharm Bull. 2022;45(12):1728-1732. doi: 10.1248/bpb.b22-00586.

2021

Original article

1. Watanabe H, Fujimura R, Hiramoto Y, Murata R, Nishida K, Bi J, Imafuku T, Komori H, Maeda H, Mukunoki A, Takeo T, Nakagata N, Tanaka M, Matsushita K, Fukagawa M, Maruyama T. An acute phase protein α1-acid glycoprotein mitigates AKI and its progression to CKD through its anti-inflammatory action. Sci Rep. 2021 Apr 12;11(1):7953. doi: 10.1038/s41598-021-87217-8.

2. Kono K, Nunoya KI, Nakamura Y, Bi J, Mukunoki A, Takeo T, Nakagata N, Hitoshi M, Yamaura Y, Imawaka H, Watanabe H, Maruyama T. Species Difference in Hydrolysis of an Ester-type Prodrug of Levodopa in Human and Animal Plasma: Different Contributions of Alpha-1 Acid Glycoprotein. Mol Pharm. 2021 May 3;18(5):1985-1991. doi: 10.1021/acs.molpharmaceut.0c01134.

3. Imafuku T, Watanabe H, Oniki K, Yoshida A, Kato H, Nakano T, Tokumaru K, Fujita I, Arimura N, Maeda H, Sakamoto Y, Kondo N, Morita A, Saruwatari J, Tanaka M, Matsushita K, Wada T, Fukagawa M, Otagiri M, Fitzgerald ML, Jinnouchi H, Maruyama T. Cysteinylated Albumin as a Potential Biomarker for the Progression of Kidney Disease in Patients With Type 2 Diabetes. Diabetes Care. 2021 Jun;44(6):e115-e117. doi: 10.2337/dc20-3003.

4. Higashihara T, Nishi H, Takemura K, Watanabe H, Maruyama T, Inagi R, Tanaka T, Nangaku M. β2-adrenergic receptor agonist counteracts skeletal muscle atrophy and oxidative stress in uremic mice. Sci Rep. 2021 Apr 28;11(1):9130. doi: 10.1038/s41598-021-88438-7.

5. Tanaka R, Suzuki Y, Watanabe H, Fujioka T, Hirata K, Shin T, Ando T, Ono H, Tatsuta R, Mimata H, Maruyama T, Itoh H. Association of CYP3A5 polymorphisms and parathyroid hormone with blood level of tacrolimus in patients with end-stage renal disease. Clin Transl Sci. 2021 Sep;14(5):2034-2042. doi: 10.1111/cts.13065.

6. Nishida K, Watanabe H, Murata R, Tokumaru K, Fujimura R, Oshiro S, Nagasaki T, Miyahisa M, Hiramoto Y, Nosaki H, Imafuku T, Maeda H, Fukagawa M, Maruyama T. Recombinant Long-Acting Thioredoxin Ameliorates AKI to CKD Transition via Modulating Renal Oxidative Stress and Inflammation. Int J Mol Sci. 2021 May 25;22(11):5600. doi: 10.3390/ijms22115600.

7. Matsusaka K, Fujiwara Y, Pan C, Esumi S, Saito Y, Bi J, Nakamura Y, Mukunoki A, Takeo T, Nakagata N, Yoshii D, Fukuda R, Nagasaki T, Tanaka R, Komori H, Maeda H, Watanabe H, Tamada K, Komohara Y, Maruyama T. α1-Acid Glycoprotein Enhances the Immunosuppressive and Protumor Functions of Tumor-Associated Macrophages. Cancer Res. 2021 Sep 1;81(17):4545-4559. doi: 10.1158/0008-5472.CAN-20-3471.

8. Kinoshita R, Ishima Y, Chuang VTG, Watanabe H, Shimizu T, Ando H, Okuhira K, Otagiri M, Ishida T, Maruyama T. The Therapeutic Effect of Human Serum Albumin Dimer-Doxorubicin Complex against Human Pancreatic Tumors. Pharmaceutics. 2021 Aug 5;13(8):1209. doi: 10.3390/pharmaceutics13081209.

9. Kato H, Watanabe H, Imafuku T, Arimura N, Fujita I, Noguchi I, Tanaka S, Nakano T, Tokumaru K, Enoki Y, Maeda H, Hino S, Tanaka M, Matsushita K, Fukagawa M, Maruyama T. Advanced oxidation protein products contribute to chronic kidney disease-induced muscle atrophy by inducing oxidative stress via CD36/NADPH oxidase pathway. J Cachexia Sarcopenia Muscle. 2021 Oct 2. doi: 10.1002/jcsm.12786.

10. Fujita I, Watanabe H, Ikegami K, Imafuku T, Ichimizu S, Chikamatsu M, Kobayashi K, Tanaka R, Yamada K, Maeda H, Maruyama T. Involvement of the Parathyroid Hormone-Related Protein on Changes in the CYP3A Expression in Cancer Cachexia. Mol Pharm. 2021 Nov 4. doi: 10.1021/acs.molpharmaceut.1c00490.

11. Hirata K, Ikeda T, Watanabe H, Maruyama T, Tanaka M, Chuang VTG, Uchida Y, Sakurama K, Nishi K, Yamasaki K, Otagiri M. The Binding of Aripiprazole to Plasma Proteins in Chronic Renal Failure Patients. Toxins (Basel). 2021 Nov 18;13(11):811. doi: 10.3390/toxins13110811.

12. Maeda H, Ishima Y, Saruwatari J, Mizuta Y, Minayoshi Y, Ichimizu S, Yanagisawa H, Nagasaki T, Yasuda K, Oshiro S, Taura M, McConnell MJ, Oniki K, Sonoda K, Wakayama T, Kinoshita M, Shuto T, Kai H, Tanaka M, Sasaki Y, Iwakiri Y, Otagiri M, Watanabe H, Maruyama T. Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH. J Control Release. 2021 Nov 29:S0168-3659(21)00634-9. doi: 10.1016/j.jconrel.2021.11.039.

13. Mizuta Y, Maeda H, Ishima Y, Minayoshi Y, Ichimizu S, Kinoshita R, Fujita I, Kai T, Hirata K, Nakamura T, Saruwatari J, Arima H, Watanabe H, Otagiri M, Maruyama T. A Mannosylated, PEGylated Albumin as a Drug Delivery System for the Treatment of Cancer Stroma Cells. 2021 Adv. funct. mater. 31 2104136

14. Matsumoto E, Oniki K, Ota-Kontani A, Seguchi Y, Sakamoto Y, Kaneko T, Imafuku T, Maeda H, Watanabe H, Maruyama T, Ogata Y, Yoshida M, Harada-Shiba M, Saruwatari J, Ogura M. Additive Effects of Drinking Habits and a Susceptible Genetic Polymorphism on Cholesterol Efflux Capacity. 2022 J Atheroscler Thromb. Online ahead of print.

15. Yan Y, Kondo N, Oniki K, Watanabe H, Imafuku T, Sakamoto Y, Shigaki T, Maruyama A, Nakazawa H, Kaneko T, Morita A, Yoshida A, Maeda H, Maruyama T, Jinnouchi H, Saruwatari J. Predictive Ability of Visit-to-Visit Variability of HbA1c Measurements for the Development of Diabetic Kidney Disease: A Retrospective Longitudinal Observational Study. 2022 J Diabetes Res. 22;2022:6934188.

16. Nakano T, Watanabe H, Imafuku T, Tokumaru K, Fujita I, Arimura N, Maeda H, Tanaka M, Matsushita K, Fukagawa M, Maruyama T. Indoxyl Sulfate Contributes to mTORC1-Induced Renal Fibrosis via The OAT/NADPH Oxidase/ROS Pathway. 2021 Toxins (Basel). Dec 18;13(12):909. doi: 10.3390/toxins13120909.

17. Murata R, Watanabe H, Nosaki H, Nishida K, Maeda H, Nishida M, Maruyama T. Long-Acting Thioredoxin Ameliorates Doxorubicin-Induced Cardiomyopathy via Its Anti-Oxidative and Anti-Inflammatory Action. 2022 Pharmaceutics. Mar 3;14(3):562. doi: 10.3390/pharmaceutics14030562.

18. Kono K, Fujimura R, Nakamura Y, Matsuura K, Nunoya K, Yamaura Y, Imawaka H, Watanabe H, Maruyama T. Hydrolase Activity of the Genetic Variants of Human Alpha-1-Acid Glycoprotein. 2022 Mol Pharm. Mar 7;19(3):798-804. doi: 10.1021/acs.molpharmaceut.1c00614. Epub 2022 Feb 18.

Review

1. Hashimoto M*, Maeda H*, Oniki K, Yasui-Furukori N, Watanabe H, Saruwatari J, Kadowaki D, New insight concerning therapeutic drug monitoring -The importance of the concept of psychonephrology-. 2022 Biol Pharm Bull. in press. *equal contribution

2020

Original article

1. Tadashi Imafuku*, Hiroshi Watanabe*,#, Kentaro Oniki, Akira Yoshida, Hiromasa Kato, Takehiro Nakano, Kai Tokumaru, Issei Fujita, Nanaka Arimura, Hitoshi Maeda, Yuki Sakamoto, Nozomi Kondo, Ayami Morita, Junji Saruwatari, Motoko Tanaka, Kazutaka Matsushita, Takashi Wada, Masafumi Fukagawa, Masaki Otagiri, Michael L. Fitzgerald, Hideaki Jinnouchi, and Toru Maruyama# *equal contribution; #equal correspondence Cysteinylated albumin as a potential biomarker for the progression of kidney disease in patients with type 2 diabetes Diabetes Care 2021

2. Hiroshi Watanabe*,#, Rui Fujimura*, Yuto Hiramoto*, Ryota Murata, Kento Nishida, Jing Bi, Tadashi Imafuku, Hisakazu Komori, Hitoshi Maeda, Ayumi Mukunoki, Toru Takeo, Naomi Nakagata, Motoko Tanaka, Kazutaka Matsushita, Masafumi Fukagawa, Toru Maruyama# *equal contribution; #equal correspondence An acute phase protein alfa1-acid glycoprotein mitigates AKI and its progression to CKD through its anti-inflammatory action Sci Rep. 2021 7953

3. Naoki Hirakawa, Yu Ishima, Ryo Kinoshita, Ryuto Nakano, Victor Tuan Giam Chuang, Hidenori Ando, Taro Shimizu, Keiichiro Okuhira, Toru Maruyama, Masaki Otagiri, Tatsuhiro Ishida Reduction-responsive and multi-drug deliverable albumin nanoparticles: an antitumor drug to Abraxane® against human pancreatic tumor-bearing mice ACS Applied Bio Materials 2021 Mar 4302-4309

4. Miwa Goto, Kazuo Azuma, Hidetoshi Arima, Shinichiro Kaneko, Taishi Higashi, Keiichi Motoyama, Akihiro Michihara, Takae Shimizu, Daisuke Kadowaki, Toru Maruyama, Masaki Otagiri, Daisuke Iohara, Fumitoshi Hirayama, Makoto Anraku Sacran, a sulfated polysaccharide, suppresses the absorption of lipids and modulates the intestinal flora in non-alcoholic steatohepatitis model rats Life Sci 2021 Mar 1;268:118991.

5. Takaya Abe, Mitsutaka Onoda, Tomohiko Matsuura, Jun Sugimura, Wataru Obara, Nariyuki Sasaki, Tetsuo Kato, Kenta Tatsumi, Toru Maruyama Evaluation of a new measurement method of indoxyl sulfate in hemodialysis patients Ther Apher Dial 2021 Feb 25(1):44-49.

6. Tadashi Imafuku, Motoko Tanaka, Koki Tokunaga, Shigeyuki Miyamura, Hiromasa Kato, Shoma Tanaka, Takehiro Nakano, Kenshiro Hirata, Daisuke Kadowaki, Hitoshi Maeda, Kazutaka Matsushita, Masaki Otagiri, Hirotaka Komaba, Masafumi Fukagawa, Hiroshi Watanabe, Toru Maruyama Effect of cinacalcet on the redox status of albumin in secondary hyperparathyroidism patients receiving hemodialysis Biol Pharm Bull 2020 43(10):1583-1590.

7. Koji Nishi, Keiki Sakurama, Hiroshi Watanabe, Toru Maruyama, Keishi Yamasaki, Masaki Otagiri Effects of uremic toxins on the binding of aripiprazole to human serum albumin Biol Pharm Bull 2020 Dec 44(3):437-441.

8. Miwa Goto, Daisuke Iohara, Akihiro Michihara, Shinsuke Ifuku, Kazuo Azuma, Daisuke Kadowaki, Toru Maruyama, Masaki Otagiri, Fumitoshi Hirayama, Makoto Anraku Effects of surface-deacetylated chitin nanofibers on non-alcoholic steatohepatitis model rats and their gut microbiota Int J Biol Macromol 2020 Dec 1;164:659-666.

9. Yu Ishima, Toru Maruyama, Masaki Otagiri, Tatsuhiro Ishida Drug delivery system for refractory cancer therapy via an endogenous albumin transport system Chem Pharm Bull (Tokyo) 2020 68(7):583-588.

10. Kento Nishida*, Hiroshi Watanabe*,#, Masako Miyahisa, Yuto Hiramoto, Hiroto Nosaki, Rui Fujimura, Hitoshi Maeda, Masaki Otagiri, Toru Maruyama# *equal contribution; #equal correspondence Systemic and sustained thioredoxin analogue prevents acute kidney injury and its-associated distant organ damage in renal ischemia reperfusion injury mice Sci Rep 2020 Nov 26;10(1):20635.

11. Mohammad Abdullah-Al-Shoeb, Kenta Sasaki, Saori Kikutani, Nanami Namba, Keiichi Ueno, Yuki Kondo, Hitoshi Maeda, Toru Maruyama, Tetsumi Irie, Yoichi Ishitsuka The late-stage protective effect of Mito-TEMPO against acetaminophen-induced hepatotoxicity in mouse and three-dimensional cell culture models Antioxidants (Basel) 2020 Oct 9;9(10):965.

12. Keishi Yamasaki, Keiki Sakurama, Koji Nishi, Hiroshi Watanabe, Toru Maruyama, Hakaru Seo, Masaki Otagiri, Kazuaki Taguchi Characterization of the Interaction of Daptomycin With Site II on Human Serum Albumin J Pharm Sci 2020 Sep 109(9):2919-2924.

13. Shoma Tanaka*, Hiroshi Watanabe*,#, Takehiro Nakano, Tadashi Imafuku, Hiromasa Kato, Kai Tokumaru, Nanaka Arimura, Yuki Enoki, Hitoshi Maeda, Motoko Tanaka, Kazutaka Matsushita, Masafumi Fukagawa, Toru Maruyama# *equal contribution; #equal correspondence Indoxyl sulfate contributes to adipose tissue inflammation through the activation of NADPH oxidase Toxins (Basel) 2020 Aug 5;12(8):502.

14. Hiroshi Watanabe*,#, Masako Miyahisa*, Mayuko Chikamatsu*, Kento Nishida, Yuki Minayoshi, Mei Takano, Shota Ichimizu, Yoshihiro Kobashigawa, Hiroshi Morioka, Hitoshi Maeda, Toru Maruyama# *equal contribution; #equal correspondence Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects J Control Release 2020 Aug 10;324:522-531.

15. Hiroshi Watanabe*,#, Jing Bi *, Ryota Murata *, Rui Fujimura , Kento Nishida, Tadashi Imafuku, Yuka Nakamura, Hitoshi Maeda, Ayumi Mukunoki, Toru Takeo, Naomi Nakagata , Yuki Kurauchi, Hiroshi Katsuki , Motoko Tanaka, Kazutaka Matsushita , Masafumi Fukagawa, Toru Maruyama# *equal contribution; #equal correspondence A synthetic retinoic acid receptor agonist Am80 ameliorates renal fibrosis via inducing the production of alpha-1-acid glycoprotein Sci Rep 2020 Jul 10, 11424 (2020)

16. Tadashi Imafuku*, Hiroshi Watanabe*,#, Takao Satoh, Takashi Matsuzaka, Tomoaki Inazumi, Hiromasa Kato, Shoma Tanaka, Yuka Nakamura, Takehiro Nakano, Kai Tokumaru, Hitoshi Maeda, Motoko Tanaka, Kazutaka Matsushita, Soken Tsuchiya, Yukihiko Sugimoto, Hitoshi Shimano, Masafumi Fukagawa, Toru Maruyama#. *equal contribution and #equal corresponding author Advanced oxidation protein products contribute to renal tubulopathy via perturbation of renal fatty acids Kidney360 2020 Aug 1 (8) 781-796

17. Ryota Tanaka, Tadashi Imafuku, Yosuke Suzuki, Kento Nishida, Kotaro Matsusaka, Toshitaka Shin, Yuhki Sato, Yu Ishima, Hiroshi Watanabe, Hiromitsu Mimata, Toru Maruyama, Hiroki Itoh Changes in redox state of albumin before and after kidney transplantation in patients with end-stage renal disease Clin Biochem 2020 Jul 81:20-26.

18. Masaki Fukunaga, Daisuke Kadowaki, Mika Mori, Satomi Hagiwara, Yuki Narita, Junji Saruwatari, Ryota Tanaka, Hiroshi Watanabe, Keishi Yamasaki, Kazuaki Taguchi, Hiroki Ito, Toru Maruyama, Masaki Otagiri, Sumio Hirata In vivo evaluation of drug dialyzability in a rat model of hemodialysis PLoS One 2020 Jun 12;15(6):e0233925.

19. Haruka Fujikawa, Yuki Sakamoto, Natsuki Masuda, Kentaro Oniki, Shunsuke Kamei, Hirofumi Nohara, Ryunosuke Nakashima, Kasumi Maruta, Taisei Kawakami, Yuka Eto, Noriki Takahashi, Toru Takeo, Naomi Nakagata, Hiroshi Watanabe, Koji Otake, Yasuhiro Ogata, Naoko H Tomioka, Makoto Hosoyamada, Tappei Takada, Keiko Ueno-Shuto, Mary Ann Suico, Hirofumi Kai, Junji Saruwatari, Tsuyoshi Shuto Higher blood uric acid in female humans and mice as a protective factor against pathophysiological decline of lung function Antioxidants (Basel) 2020 May 9(5):387

20. Kentaro Oniki, Hirofumi Nohara, Ryunosuke Nakashima, Yui Obata, Narumi Muto, Yuki Sakamoto, Keiko Ueno-Shuto, Tadashi Imafuku, Yu Ishima 5 , Hiroshi Watanabe, Toru Maruyama, Koji Otake, Yasuhiro Ogata, Mary Ann Suico, Hirofumi Kai, Tsuyoshi Shuto, Junji Saruwatari The DsbA-L gene is associated with respiratory function of the elderly via its adiponectin multimeric or antioxidant properties Sci Rep 2020 Apr 6;10(1):5973.

21. Rui Fujimura*, Hiroshi Watanabe*,#, Kento Nishida, Yukio Fujiwara, Tomoaki Koga T, Jing Bi, Tadashi Imafuku, Kazuki Kobayashi, Hisakazu Komori, Masako Miyahisa, Hitoshi Maeda, Motoko Tanaka, Kazutaka Matsushita, Takashi Wada, Masafumi Fukagawa, Toru Maruyama T# *equal contribution and #equal corresponding author alfa1-acid glycoprotein attenuates adriamycin-induced nephropathy via CD163 expressing macrophages induction. Kidney360 2020 May 1 (5) 343-353

Book

1. Hiroshi Watanabe#, Hitromasa Kato, Yuki Enoki, Hitoshi Maeda, Toru Maruyama. #correspondence Uremic solutes and sarcopenia. Springer Book 2020 Chapter 9

2. Hiroshi Watanabe#, Yuki Enoki, Toru Maruyama T #correspondence Molecular mechanism of muscle wasting in CKD Springer Book 2020 Chapter 2

3. 猿渡淳二、金子哲也、前田仁志 専門医のための臨床精神神経薬理学テキスト 星和書店 2021年3月 64-72

Others

渡邊博志、丸山徹アンメットな腎疾患の病態制御を指向した診断・治療戦略への挑戦 渡邊博志、丸山徹 日本薬学会 2020年12月号 1109-1111 ファルマシア

2019

Original article

1. Fujimura R*#, Watanabe H*#, Nishida K, Fujiwara Y, Koga T, Bi J, Imafuku T, Kobayashi K, Komori H, Miyahisa M, Maeda H, Tanaka M, Matsushita K, Wada T, Fukagawa M, Maruyama T#. *equal controbution, #equal corresponding author α1-acid glycoprotein attenuates adriamycin-induced nephropathy via CD163 expressing macrophages induction Kidney360 2020 Mar in press

2. Nishida K*#, Watanabe H*#, Miyahisa M, Hiramoto Y, Nosaki H, Fujimura R, Maeda H, Otagiri M, and Maruyama M#. *equal controbution, #equal corresponding author Systemic and sustained thioredoxin analogue prevents acute kidney injury and its-associated distant organ damage in renal ischemia reperfusion injury mice Sci Rep. in press

3. Oniki K, Nohara H, Nakashima R, Obata Y, Muto N, Sakamoto Y, Ueno-Shuto K, Imafuku T, Ishima Y, Watanabe H, Maruyama T, Otake K, Ogata Y, Suico MA, Kai H, Shuto T, and Saruwatari J. The DsbA-L gene is associated with respiratory function of the elderly via its adiponectin multimeric or antioxidant properties Sci Rep. in press

4. Son K, Ueda M, Taguchi K, Maruyama T, Takeoka S, Ito Y. Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes. J Control Release. 2020 Mar 17 pii: S0168-3659(20)30174-7.

5. Oniki K, Kawakami T, Nakashima A, Miyata K, Watanabe T, Fujikawa H, Nakashima R, Nasu A, Eto Y, Takahashi N, Nohara H, Suico MA, Kotani S, Obata Y, Sakamoto Y, Seguchi Y, Saruwatari J, Imafuku T, Watanabe H, Maruyama T, Kai H, Shuto T. Melinjo seed extract increases adiponectin multimerization in physiological and pathological conditions. Sci Rep. 2020 Mar 9 10(1):4313.

6. Taguchi K, Ogaki S, Nagasaki T, Yanagisawa H, Nishida K, Maeda H, Enoki Y, Matsumoto K, Sekijima H, Ooi K, Ishima Y, Watanabe H, Fukagawa M, Otagiri M, Maruyama T. Carbon monoxide rescues the developmental lethality of experimental rat models of rhabdomyolysis-induced acute kidney injury J Pharmacol Exp Ther. 2020 Mar 372(3):355-365.

7. Ishima Y, Watanabe K, Chuang VTG, Takeda I, Kuroda T, Ogawa W, Watanabe H, Iwao Y, Ishida T, Otagiri M, Maruyama T. S-Nitrosated alpha-1-acid glycoprotein exhibits antibacterial activity against multidrug-resistant bacteria strains and synergistically enhances the effect of antibiotics. FASEB Bioadv. 2019 Feb 4;1(3):137-150.

8. Taguchi K, Matsumoto K, Maruyama T, Otagiri M. Strategy of Drug Development Based on the Bioactive Gas-carrying Capacity of Hemoglobin. Yakugaku Zasshi. 2020 140(2):141-146.

9. Maeda H#, Minayoshi Y, Ichimizu S, Mizuta Y, Nagasaki T, Matsusaka K, Oshiro S, Oniki K, Saruwatari J, Ishima Y, Watanabe H, Otagiri M, Maruyama T#. #equal corresponding author Repeated Administration of Kupffer Cells-Targeting Nanoantioxidant Ameliorates Liver Fibrosis in an Experimental Mouse Model. Biol Pharm Bull. 2020 43(1):93-101.

10. Ishima Y, Mimono A, Tuan Giam Chuang V, Fukuda T, Kusumoto K, Okuhira K, Suwa Y, Watanabe H, Ishida T, Morioka H, Maruyama T, Otagiri M. Albumin domain mutants with enhanced Aβ binding capacity identified by phage display analysis for application in various peripheral Aβ elimination approaches of Alzheimer's disease treatment. IUBMB Life. 2020 Apr 72(4):641-651.

11. Kono K, Fukuchi Y, Okawa H, Nunoya KI, Imawaka H, Watanabe H, Maruyama T. Unique Hydrolysis of an Ester-Type Prodrug of Levodopa in Human Plasma: Relay-Type Role Sharing between Alpha-1 Acid Glycoprotein and Human Serum Albumin. Mol Pharm. 2019 Oct 7 16(10):4131-4138.

12. Matsusaka K, Ishima Y, Maeda H, Kinoshita R, Ichimizu S, Taguchi K, Giam Chuang VT, Nishi K, Yamasaki K, Otagiri M, Watanabe H, Maruyama T. α1-Acid Glycoprotein Has the Potential to Serve as a Biomimetic Drug Delivery Carrier for Anticancer Agents. J Pharm Sci. 2019 Nov 108(11):3592-3598.

13. Ichimizu S*#, Watanabe H*#, Maeda H, Hamasaki K, Ikegami K, Chuang VTG, Kinoshita R, Nishida K, Shimizu T, Ishima Y, Ishida T, Seki T, Katsuki H, Futaki S, Otagiri M, Maruyama T#. *equal controbution, #equal corresponding author Cell-penetrating mechanism of intracellular targeting albumin: Contribution of macropinocytosis induction and endosomal escape. J Control Release. 2020 Mar 17 pii: S0168-3659(20)30174-7.

14. Hirata K, Watanabe H, Toyoda M, Sugimoto R, Ikegami K, Imafuku T, Matsuzaka K, Ichimizu S, Maeda H, Uekihara S, Jingami S, Maruyama T. Effect of Serum Parathyroid Hormone on Tacrolimus Therapy in Kidney Transplant Patients: A Possible Biomarker for a Tacrolimus Dosage Schedule. Biol Pharm Bull. 2019 42(5):786-791.

15. Ikeda M, Ishima Y, Chuang VTG, Sakai M, Osafune H, Ando H, Shimizu T, Okuhira K, Watanabe H, Maruyama T, Otagiri M, Akaike T, Ishida T. Distribution of Polysulfide in Human Biological Fluids and Their Association with Amylase and Sperm Activities. Molecules. 2019 Apr 30;24(9). pii: E1689.

Review

1. Watanabe H*, Enoki Y, Maruyama T. *corresponding author Sarcopenia in Chronic Kidney Disease: Factors, Mechanisms, and Therapeutic Interventions. Biol Pharm Bull. 2019 42(9):1437-1445.

2. 渡邊博志*, 今福匡司, 丸山徹 *corresponding author 酸化ストレス関連疾患における酸化型・還元型アルブミンモニタリングと臨床的有用性Proteome letters 2019 4: 9-17

Book

1. Watanabe H*, Enoki Y, Maruyama T *corresponding author Molecular mechanism of muscle wasting in CKD. Recent advances of sarcopenia and frailty in CKD Springer 2020 15-34

2018

1. Bi J, Watanabe H, Fujimura R, Nishida K, Nakamura R, Oshiro S, Imafuku T, Komori H, Miyahisa M, Tanaka M, Matsushita K, Maruyama T, A downstream molecule of 1,25-dihydroxyvitamin D3, alpha-1-acid glycoprotein, protects against mouse model of renal fibrosis, Sci Rep  (2018) Nov 26;8(1):17329.

2. Taguchi K, Nagao S, Maeda H, Yanagisawa H, Sakai H, Yamasaki K, Wakayama T, Watanabe H, Otagiri M, Maruyama T, Biomimetic carbon monoxide delivery based on hemoglobin-vesicles ameliorates acute pancreatitis in mice via the regulation of macrophage and neutrophil activity, Drug Deliv, 25, 1266-1274 (2018).

3. Minayoshi Y, Maeda H, Yanagisawa, H, Hamasaki K, Mizuta Y, Nishida N, Kinoshita R, Enoki Y, Imafuku T, Chuang VTG, Koga T, Fujiwara Y, Takeya M, Sonoda K, Wakayama T, Taguchi K, Ishima Y, Ishida T, Iwakiri Y, Tanaka M, Sasaki Y, Watanabe H, Otagiri M, Maruyama T, Development of kupffer cell targeting type-Ⅰinterferon for the treatment of hepatitis via Inducing anti-inflammatory and immunomodulatory actions, Drug Deliv., 25, 1067-1077, (2018).

4. Yamasaki K, Sakurama K,  Kawai A, Chuang VTG, Kanamori Y, Osa M, Taguchi K, Seo H, Maruyama T, Imoto S, Otagiri M,  An analysis of the binding of aripiprazole, a novel antipsychotic, to human serum albumin: The importance of a chloro-group in the chemical structure, ACS Omega, 3, 13790-13797(2018).

5. Watanabe H, Maruyama T, Role of parathyroid hormone in regulating transporter and metabolizing enzyme function, Ther Apher Dial, 22, 251-254 (2018). 

6. Ichimizu S, Watanabe H, Maeda H, Hamasaki K, Nakamura Y, Chuang VTG, Kinoshita R, Nishida K, Tanaka R, Enoki Y, Ishima Y, Kuniyasue A, Kobashigawa Y, Morioka H, Futaki S,  Otagiri M, Maruyama T, Design and tuning of a cell-penetrating albumin derivative as a versatile nanovehicle for intracellular drug delivery, J Control Release, 277, 23-34 (2018).

7. Anraku M, Gebicki JM, Iohara D,  Tomida H, Uekama K, Maruyama T, Hirayama F, Otagiri M, Antioxidant activities of chitosans and its derivatives in in vitro and in vivo studies, Carbohydr Polym, 199, 141-149 (2018). 

8. Yamasaki K, Nishi K, Anraku M, Taguchi K, Maruyama T, Otagiri M, Metal-catalyzed oxidation of human serum albumin does not alter the interactive binding to the two principal drug binding sites, Biochem Biophys Rep, 14, 155-160 (2018).

9. Muraya N, Kadowaki D, Miyamura S, Kitamura K, Uchimura K, Narita Y, Miyamoto Y, Chuang V, Taguchi K, Maruyama T, Otagiri M, Hirata S, Benzbromarone attenuates oxidative stress in model rats with angiotensin II- and salt-induced hypertension, Oxidative Medicine and Cellular Longevity, 2018, Article ID 7635274

10. Oniki K, Watanabe T, Kudo M, Izuka, T, Ono T, Matsuda K, Sakamoto Y, Nagaoka K, Imafuku T, Ishima Y, Watanabe H, Maruyama T, Otake K, Ogata, Y, Saruwatari J, Modeling of the weight status and risk of non-alcoholic fatty liver disease in elderly individuals: The potential impact of the DsbA-L polymorphism on the weight status, CPT Pharmacometrics Syst Pharmacol, 7, 384-393 (2018).

11. Tanaka KI, Shimoda M, Chuang VTG, Nishida N, Kawahara M, Ishida T, OtagiriM, Maruyama T, Ishima Y, Thioredoxin-albumin fusion protein prevents copper enhanced zinc-induced neurotoxicity via its antioxidative activity, Int J Pharm,  535, 140-147 (2018).       

12. Oshiro S,  Ishima Y, Maeda H, Honda N, Bi J, Kinoshita R, Ikeda M, Iwao Y, Imafuku T,  Nishida K, Miyamura S, Watanabe H, Otagiri M, Maruyama T, Dual therapeutic effects of an albumin-based nitric oxide donor on two experimental models of chronic kidney disease, J Pharm Sci, 107, 848-855 (2018).

13. Ikeda M,  Ishima Y, Kinoshita R, Chuang VTG,  Tasaka N, Matsuo N, Watanabe H, Shimizu T, Ishida T, Otagiri M, Maruyama T, A novel S-sulfhydrated human serum albumin preparation suppresses melanin synthesis, Redox Biology, 14:354-360 (2018).

2017

 1. Ichimizu S*, Watanabe H*, Maeda H, Hamasaki K, Nakamura Y, Chuang VTG, Kinoshita R, Nishida K, Tanaka R, Enoki Y, Ishim Y, Kuniyasu A, Kobashigawa Y, Morioka H, Futaki S, Otagiri M, Maruyama T. Design and tuning of a cell-penetrating albumin derivative as a versatile nanovehicle for intracellular drug delivery. J Control Release (in press) *equal contribution

2. Oniki　K, Watanabe T, Kudo M, Izuka T, Ono T, Matsuda K, Sakamoto Y, Nagaoka K, Imafuku T, Ishima Y, Watanabe H, Maruyama T, Otake K, Ogata Y, Saruwatari J. Modeling of the weight status and risk of non-alcoholic fatty liver disease in elderly individuals: The potential impact of the DsbA-L polymorphism on the weight status. CPT Pharmacometrics Syst Pharmacol. (in press)

 3. Tanaka KI, Shimoda M, Chuang VTG, Nishida K, Kawahara M, Ishida T, Otagiri M, Maruyama T, Ishima Y. Thioredoxin-albumin fusion protein prevents copper enhanced zinc-induced neurotoxicity via its antioxidative activity. Int J Pharm. 2018 Jan 15;535(1-2):140-147. doi: 10.1016/j.ijpharm.2017.11.012. Epub 2017 Nov 6.

4. Oshiro S, Ishima Y, Maeda H, Honda N, Bi J, Kinoshita R, Ikeda M, Iwao Y, Imafuku T, Nishida K, Miyamura S, Watanabe H, Otagiri M, Maruyama T. Dual therapeutic effects of an albumin-based nitric oxide donor on 2 experimental models of chronic kidney disease. J Pharm Sci. 2018 Mar;107(3):848-855.

5. Shimoishi K, Anraku M, Uto A, Iohara D, Hirayama F, Kadowaki D, Zingami S, Maruyama T, Otagiri M. A Comparison of the Phosphorus Content in Prescription Medications for Hemodialysis Patients in Japan. Yakugaku Zasshi. 2017;137(7):903-908. doi: 10.1248/yakushi.17-00006.

6. Yamasaki K, Hyodo S, Taguchi K, Nishi K, Yamaotsu N, Hirono S, Chuang VTG, Seo H, Maruyama T, Otagiri M. Long chain fatty acids alter the interactive binding of ligands to the two principal drug binding sites of human serum albumin. PLoS One. 2017 Jun 29;12(6):e0180404. doi: 10.1371/journal.pone.0180404. eCollection 2017.

7. Yamasaki K, Enokida T, Taguchi K, Miyamura S, Kawai A, Miyamoto S, Maruyama T, Seo H, Otagiri M. Species Differences in the Binding of Sodium 4-Phenylbutyrate to Serum Albumin. J Pharm Sci. 2017 Sep;106(9):2860-2867. doi: 10.1016/j.xphs.2017.04.025. Epub 2017 Apr 26.

8. Taguchi K, Yamasaki K, Sakai H, Maruyama T, Otagiri M. The Use of Hemoglobin Vesicles for Delivering Medicinal Gas for the Treatment of Intractable Disorders. J Pharm Sci. 2017 Sep;106(9):2392-2400. doi: 10.1016/j.xphs.2017.04.006. Epub 2017 Apr 13. Review.

9. Ikeda M, Ishima Y, Kinoshita R, Chuang VTG, Tasaka N, Matsuo N, Watanabe H, Shimizu T, Ishida T, Otagiri M, Maruyama T. A novel S-sulfhydrated human serum albumin preparation suppresses melanin synthesis. Redox Biol. 2017 Oct 11;14:354-360.

10. Matsushita S, Nishi K, Iwao Y, Ishima Y, Watanabe H, Taguchi K, Yamasaki K, Maruyama T, Otagiri M. Recombinant human serum albumin containing 3 copies of domain I, has significant in vitro antioxidative capacity compared to the wild-type. Biol Pharm Bull. 2017;40(10):1813-1817.

 11. Watanabe H*#, Sugimoto R*, Ikegami K, Enoki Y, Imafuku T, Fujimura R, Bi J, Nishida K, Sakaguchi Y, Murata M, Maeda H, Hirata K, Jingami S, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Maruyama T#. Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism. Biochem Pharmacol. *equal contribution, #equal corresponding author 2017 Dec 1;145:192-201.

12. Kinoshita R, Ishima Y, Chuang VTG, Nakamura H, Fang J, Watanabe H, Shimizu T, Okuhira K, Ishida T, Maeda H, Otagiri M, Maruyama T. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer. Biomaterials. 2017 Sep;140:162-169.

 13. Ikeda M, Ishima Y, Chuang VTG, Ikeda T, Kinoshita R, Watanabe H, Ishida T, Otagiri M, Maruyama T. Apoptosis induction of poly-S-nitrosated human serum albumin in resistant solid tumor under hypoxia can be restored by phosphodiesterase 5 inhibition. Nitric Oxide. 2017 Apr 13. pii: S1089-8603(16)30269-5.

14. Ikeda M, Ishima Y, Shibata A, Chuang VTG, Sawa T, Ihara H, Watanabe H, Xian M, Ouchi Y, Shimizu T, Ando H, Ukawa M, Ishida T, Akaike T, Otagiri M, Maruyama T. Quantitative determination of polysulfide in albumins, plasma proteins and biological fluid samples using a novel combined assays approach. Anal Chim Acta. 2017 May 29;969:18-25.

 15. Enoki Y*, Watanabe H*, Arake R, Fujimura R, Ishiodori K, Imafuku T, Nishida K, Sugimoto R, Nagao S, Miyamura S, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Maruyama T. Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction. J Cachexia Sarcopenia Muscle. *equal contribution 2017 Oct;8(5):735-747.

16. Yamasaki K, Sato H, Minagoshi S, Kyubun K, Anraku M, Miyamura S, Watanabe H, Taguchi K, Seo H, Maruyama T, Otagiri M. The Binding of Silibinin, the Main Constituent of Silymarin, to Site I on Human Serum Albumin. Biol Pharm Bull. 2017;40(3):310-317

17. Anraku M, Tabuchi R, Ifuku S, Nagae T, Iohara D, Tomida H, Uekama K, Maruyama T, Miyamura S, Hirayama F, Otagiri M. An oral absorbent, surface-deacetylated chitin nano-fiber ameliorates renal injury and oxidative stress in 5/6 nephrectomized rats. Carbohydr Polym. 2017 Apr 1;161:21-25. doi: 10.1016/j.carbpol.2016.12.057. Epub 2016 Dec 23.

18. Setoyama H, Tanaka M, Nagumo K, Naoe H, Watanabe T, Yoshimaru Y, Tateyama M, Sasaki M, Watanabe H, Otagiri M, Maruyama T, Sasaki Y. Oral branched-chain amino acid granules improve structure and function of human serum albumin in cirrhotic patients. J Gastroenterol. 2017, Jun;52(6):754-765. 

19. Sugimoto R*, Watanabe H*, Ikegami K, Enoki Y, Imafuku T, Sakaguchi Y, Murata M, Nishida K, Miyamura M, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Toru Maruyama. The down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. Kidney Int. 91: 658-670 (2017) *equal contribution

2016

1. Watanabe H, Imafuku T, Otagiri M, Maruyama T. Clinical Implications Associated with the Posttranslational Modification-Induced Functional Impairment of Albumin in Oxidative Stress Related Disease. J Pharm Sci. Review (in press)

2. Yamasaki K, Sato H, Minagoshi S, Kyubun K, Anraku M, Miyamura S, Watanabe H, Taguchi K, Seo H, Maruyama T, Otagiri M. The Binding of Silibinin, the Main Constituent of Silymarin, to Site I on Human Serum Albumin. Biol Pharm Bull. 2017;40(3):310-317

3. Anraku M, Tabuchi R, Ifuku S, Nagae T, Iohara D, Tomida H, Uekama K, Maruyama T, Miyamura S, Hirayama F, Otagiri M. An oral absorbent, surface-deacetylated chitin nano-fiber ameliorates renal injury and oxidative stress in 5/6 nephrectomized rats. Carbohydr Polym. 2017 Apr 1;161:21-25.

4. Shuto T, Kamei S, Nohara H, Fujikawa H, Tasaki Y, Sugahara T, Ono T, Matsumoto C, Sakaguchi Y, Maruta K, Nakashima R, Kawakami T, Suico MA, Kondo Y, Ishigami A, Takeo T, Tanaka KI, Watanabe H, Nakagata N, Uchimura K, Kitamura K, Li JD, Kai H. Pharmacological and genetic reappraisals of protease and oxidative stress pathways in a mouse model of obstructive lung diseases. Sci Rep. 2016 Dec 16;6:39305. doi: 10.1038/srep39305.

5. Setoyama H, Tanaka M, Nagumo K, Naoe H, Watanabe T, Yoshimaru Y, Tateyama M, Sasaki M, Watanabe H, Otagiri M, Maruyama T, Sasaki Y. Oral branched-chain amino acid granules improve structure and function of human serum albumin in cirrhotic patients. J Gastroenterol.  (in press)

6. Sugimoto R*, Watanabe H*, Ikegami K, Enoki Y, Imafuku T, Sakaguchi Y, Murata M, Nishida K, Miyamura M, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Toru Maruyama. The down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. Kidney Int. 91: 658-670 (2017) *equal contribution

7. Nagao S, Taguchi K, Sakai H, Yamasaki K, Watanabe H, Otagiri M, Maruyama T. Carbon monoxide-bound hemoglobin vesicles ameliorate multiorgan injuries induced by severe acute pancreatitis in mice by their anti-inflammatory and antioxidant properties. Int J Nanomedicine. 11:5611-5620 (2016)

8. Shibata A, Ishima Y, Ikeda M, Sato H, Imafuku T, Chuang VT, Ouchi Y, Abe T, Watanabe H, Ishida T, Otagiri M, Maruyama T. Human serum albumin hydropersulfide is a potent reactive oxygen species scavenger in oxidative stress conditions such as chronic kidney disease. Biochem Biophys Res Commun. 479:578-583 (2016)

9. Enoki Y, Watanabe H, Arake R, Sugimoto R, Imafuku T, Tominaga Y, Ishima Y, Kotani S, Nakajima M, Tanaka M, Matsushita K, Fukagawa M, Otagiri M, Maruyama T. Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1. Sci Rep. 6:32084 (2016)

10. Nagao S, Taguchi K, Miyazaki Y, Wakayama T, Chang VTG, Yamasaki K, Watanabe H, Sakai H, Otagiri M Maruyama T. Evaluation of a new type of nano-sized carbon monoxide donor on treating mice with experimentally induced colitis. J Control Release 234, 49-58 (2016)

11. Enokida T, Yamasaki K, Okamoto Y, Taguchi K, Ishiguro T, Maruyama T, Seo H, Otagiri M. Tyrosine411 and Arginine410 of Human Serum Albumin Play an Important Role in the Binding of Sodium 4-Phenylbutyrate to Site II. J Pharm Sci. 2016 Jun;105(6):1987-94.

12. Yamada K, Yokomaku K, Haruki R, Taguchi K, Nagao S, Maruyama T, Otagiri M, Komatsu T. Influence of Molecular Structure on O2-Binding Properties and Blood Circulation of Hemoglobin?Albumin Clusters. PLoS One. 2016 Feb 19;11(2):e0149526.

13. Taguchi K, Nagao S, Yamasaki K, Sakai H, Seo H, Maruyama T, Otagiri M. Biological Responsiveness and Metabolic Performance of Liposome-Encapsulated Hemoglobin (Hemoglobin-Vesicles) in Apolipoprotein E-Deficient Mice after Massive Intravenous Injection. PLoS One. 2016 Feb 19;11(2):e0149526.

14. Tanaka M, Miyamura S, Imafuku T, Tominaga Y, Maeda H, Anraku M, Yamasaki K, Kadowaki D, Ishima Y, Watanabe H, Okuda T, Itoh K, Matsushita K, Fukagawa M, Otagiri M, Maruyama T. Effect of a Ferric Citrate Formulation, a Phosphate Binder, on Oxidative Stress in Chronic Kidney Diseases-Mineral and Bone Disorder Patients Receiving Hemodialysis: A Pilot Study. Biol Pharm Bull. 39:1000-1006 (2016)

15. Yamamoto E, Hirata Y, Tokitsu T, Kusaka H, Tabata N, Tsujita K, Yamamuro M, Kaikita K, Watanabe H, Hokimoto S, Maruyama T, Ogawa H. The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction. ESC Heart Failure 3, 53-59 (2016)

16. Miyamura S, Imafuku T, Anraku M, Taguchi K, Yamasaki K, Tominaga Y, Maeda H, Ishima Y, Watanabe H, Otagiri M, Maruyama T. Comparison of Posttranslational Modification and the Functional Impairment of Human Serum Albumin in Commercial Preparations. J Pharm Sci. 105, 1043-1049 (2016)

2015

1.Tanaka M, Miyamura S, Imafuku T, Tominaga Y, Anraku M, Yamasaki K, Kadowaki D, Ishima Y, Watanabe H, Okuda T, Itoh K, Matsushita K, Fukagawa M, Otagiri M, Maruyama T, Effect of a ferric citrate formulation, a phosphate binder, on oxidative stress in chronic kidney diseases-mineral and bone disorder patients receiving hemodialysis: A pilot study, Biol Pharm Bull, 2016 in press

2. Enokida T, Yamasaki K, Okamoto Y, Taguchi K, Ishiguro T, Maruyama T, Seo H, Otagiri M, Tyrosine411 and Arginine410 of Human Serum Albumin Play an Important Role in the Binding of Sodium 4-Phenylbutyrate to Site II, J Pharm Sci, 2016 in press

3.Miyamura S, Imafuku T, Anraku M, Taguchi K, Yamasaki K, Tominaga Y, Maeda H, Ishima Y, Watanabe H, Otagiri M, Maruyama T, Comparison of Posttranslational Modification and the Functional Impairment of Human Serum Albumin in Commercial Preparations, J Pharm Sci.105: 1043-9 (2016).

4.Yamada K, Yokomaku K, Haruki R, Taguchi K, Nagao S, Maruyama T, Otagiri M, Komatsu T, Influence of Molecular Structure on O2-Binding Properties and Blood Circulation of Hemoglobin‒Albumin Clusters. PLoS One. 2016 Feb 19;11(2):e0149526. doi: 10.1371/journal.pone.0149526. eCollection 2016.

5.Yamamoto E, Hirata Y, Tokitsu T, Kusaka H, Tabata N, Tsujita K, Yamamuro M, Kaikita K, Watanabe H, Hokimoto S, Maruyama T, Ogawa H, The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction, ESC Heart Failure, 3, 53–59 (2016).

6.Taguchi K, Nagao S, Yamasaki K, Sakai H, Seo H, Maruyama T, Otagiri M, Biological Responsiveness and Metabolic Performance of Liposome-Encapsulated Hemoglobin (Hemoglobin-Vesicles) in Apolipoprotein E-Deficient Mice after Massive Intravenous Injection, Biol Pharm Bull, 38, 1606-16 (2015).

7.Ishima Y, Narisoko T, Kragh-Hansen U, Kotani S, Nakajima M, Otagiri M, Maruyama T, Nitration of indoxyl sulfate facilitates its cytotoxicity in human renal proximal tubular cells via expression of heme oxygenase-1, Biochem Biophys Res Commun, 465, 481-7 (2015).

8.Kinoshita R, Ishima Y, Ikeda M, Kragh-Hansen U, Fang J, Nakamura H, Chuang VTG, Tanaka R, Maeda H, Kodama A, Watanabe H, Maeda H, Otagiri M, Maruyama T, S-Nitrosated human serum albumin dimer as novel nano EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes, J Control Release, 217:1-9 (2015).

9.Yamamoto S, Kazama J, Omori K, Matsuo K, Takahashi Y, Kawamura K, Matsuto T, Watanabe H, Maruyama T, and Narita I, Continuous Reduction of Protein-Bound Uraemic Toxins with Improved Oxidative Stress by Using the Oral Charcoal Adsorbent AST-120 in Haemodialysis Patients, Sci Rep 2015, 5:14381. doi: 10.1038/srep14381.

10.Ogaki S, Taguchi K,  Maeda H, Watanabe H, Ishima Y,  Otagiri M, Maruyama T, Kupffer cell inactivation by carbon monoxide bound to red blood cells preserves hepatic cytochrome P450 via anti-oxidant and anti-inflammatory effects exerted through the HMGB1/TLR-4 pathway during resuscitation from hemorrhagic shock, Biochemical Pharmacol, 97, 310-9 (2015).

11.Hashimoto M, Taguchi K, Ogaki S, Watanabe H, Kinoshita M, Nishikawa K, Takeoka S, Ikeda Y, Handa M, Otagiri M, Maruyama T, Pharmacokinetic Properties of Single and Repeated Injection of Liposomal Platelet Substitute in a Rat Model of Red Blood Cell Transfusion-Induced Dilutional Thrombocytopenia, J Pharm Sci, 104: 3968-76 (2015).

12.Haruki R, Kimura T, Iwasaki H, Yamada K, Kamiyama I, Kohno M, Taguchi K,  Nagao S, Maruyama T, Otagiri M, Komatsu T, Safety Evaluation of Hemoglobin Albumin Cluster “HemoAct” as a Red Blood Cell Substitute, Sci Rep 2015, 5:12778. doi: 10.1038/srep12778.

13.Nishida K, Watanabe H, Ogaki S, Kodama A, Tanaka R, Imafuku T, Ishima Y, Chuang VTG, Toyoda M, Kondoh M, Wu Q, Fukagawa M, Otagiri M, Maruyama T, Renoprotective effect of long acting thioredoxin by modulating oxidative stress and macrophage migration inhibitory factor against rhabdomyolysis-associated acute kidney injury, Sci Rep 2015, 5:14471. doi: 10.1038/srep14471.

14.Enoki Y, Ishima Y, Tanaka R, Sato K, Kimachi K, Shirai T, Watanabe H, Chuang VTG, Fujiwara Y, Takeya M, Otagiri M, Maruyama T, Pleiotropic effects of levofloxacin, fluoroquinolone antibiotics, against influenza virus-induced lung injury, PLoS ONE, 10(6):e0130248. doi: 10.1371/journal.pone.0130248. eCollection 2015.

15.Anraku M, Shintomo R, Taguchi K, Kragh-Hansen U, Kai T, Maruyama T, Otagiri M, Amino acids of importance for the antioxidant activity of human serum albumin as revealed by recombinant mutants and genetic variants, Life Sci, 134, 36-41 (2015).

16.Anraku M, Iohara D, Wada K, Taguchi K, Maruyama T, Otagiri M, Uekama K, Hirayama F, Antioxidant and renoprotective activity of 2-hydroxypropyl-β-cyclodextrin in nephrectomized rats, J Pharm Pharmacol (2015) in press.

17.Yamamoto E, Hirata Y, Tokitsu T, Kusaka H, Sakamoto K, Yamamuro M, Kaikita K, Watanabe H, Hokimoto S, Sugiyama S, Maruyama T, Ogawa H, The pivotal role of eNOS uncoupling in vascular endothelial dysfunction in patients with heart failure with preserved ejection fraction, Int J Cardiol, 190, 335-337 (2015).

18.Taguchi K, Hashimoto M, Ogaki S, Watanabe H, Takeoka S, Ikeda Y, Handa M, Otagiri M, Maruyama T, Effect of Repeated Injections of Adenosine Diphosphate-Encapsulated Liposomes Coated with a Fibrinogen γ-Chain Dodecapeptide Developed as a Synthetic Platelet Substitute on Accelerated Blood Clearance in a Healthy and an Anticancer Drug-Induced Thrombocytopenia Rat Model. J Pharm Sci, 104, 3084-9 (2015).

19.Kadowaki D, Anraku M, Sakaya M, Hirata S, Maruyama T, Otagiri M, Olmesartan protects endothelial cells against oxidative stress-mediated cellular injury, Clin Exp Nephrol, 19: 1007-14 (2015).

20.Kadowaki D, Sakaguchi S, Miyamoto Y, Taguchi K, Muraya N, Narita Y, Sato K, Chuang VT, Maruyama T, Otagiri M, Hirata S, Direct radical scavenging activity of benzbromarone provides beneficial antioxidant properties for hyperuricemia treatment. Biol Pharm Bull, 38: 487-92 (2015).

21.Watanabe H, Miyamoto Y,  Enoki Y, Ishima Y, Kadowaki D, Kotani S, Nakajima M, Tanaka M, Matsushita K, Mori Y, Kakuta T, Fukagawa M, Otagiri M, Maruyama T, p-Cresyl sulfate, a uremic toxin, causes vascular endothelial and smooth muscle cell damages by inducing oxidative stress, Pharmacology Research & Perspectives, 2015 3(1):e00092. doi: 10.1002/prp2.92.

22.Taguchi K, Chuang VT, Yamasaki K, Urata Y, Tanaka R, Anraku M, Seo H, Kawai K, Maruyama T, Komatsu T, Otagiri M. Cross-linked human serum albumin dimer has the potential for use as a plasma-retaining agent for the fatty acid-conjugated antidiabetic drugs. J Pharm Pharmacol, 67, 255-263 (2015).

23.Maeda H, Hirata K, Watanabe H, Ishima Y, Chuang VTG, Taguchi K, Inatsu A, Kinoshita M, Tanaka M, Sasaki Y, Otagiri M, Maruyama T, Polythiol-containing, recombinant mannosylated-albumin is a superior CD68+/CD206+ Kupffer cell-targeted nano-antioxidant for the treatment of two acute hepatitis models, J Pharm Exp Ther, 352, 244-57 (2015).

24.Ishima Y, Inoue A, Fang J, Kinoshita R, Ikeda M,  Watanabe H, Maeda H, Otagiri M, Maruyama T, Poly-S-nitrosated human albumin enhances the antitumor and antimetastasis effect of bevacizumab, partly by inhibiting autophagy via the generation of nitric oxide, Cancer Sci, 106, 194-200 (2015).

 

2014

1.Watanabe H, Miyamoto Y, Enoki Y, Ishima Y, Kadowaki D, Kotani S, Nakajima M, Tanaka M, Matsushita K, Mori Y, Kakuta T, Fukagawa M, Otagiri M, Maruyama T. p-Cresyl sulfate, a uremic toxin, causes vascular endothelial and smooth muscle cell damages by inducing oxidative stress. Pharmacol Res Perspect. 2015 Feb;3(1):e00092.

2.Taguchi K, Chuang VT, Yamasaki K, Urata Y, Tanaka R, Anraku M, Seo H, Kawai K, Maruyama T, Komatsu T, Otagiri M. Cross-linked human serum albumin dimer has the potential for use as a plasma-retaining agent for the fatty acid-conjugated antidiabetic drugs. J Pharm Pharmacol. 2015 Feb;67(2):255-63.

3.Ishima Y, Inoue A, Fang J, Kinoshita R, Ikeda M, Watanabe H, Maeda H, Otagiri M, Maruyama T. Poly-S-nitrosated human albumin enhances the antitumor and antimetastasis effect of bevacizumab, partly by inhibiting autophagy through the generation of nitric oxide. Cancer Sci. 2015 Feb;106(2):194-200.

4.Tanaka R, Ishima Y, Enoki Y, Kimachi K, Shirai T, Watanabe H, Chuang VT, Maruyama T, Otagiri M. Therapeutic impact of human serum albumin-thioredoxin fusion protein on influenza virus-induced lung injury mice. Front Immunol. 2014 Nov 5;5:561.

5.Maeda H, Hirata K, Watanabe H, Ishima Y, Chuang VT, Taguchi K, Inatsu A, Kinoshita M, Tanaka M, Sasaki Y, Otagiri M, Maruyama T. Polythiol-containing, recombinant mannosylated-albumin is a superior CD68+/CD206+ Kupffer cell-targeted nanoantioxidant for treatment of two acute hepatitis models. J Pharmacol Exp Ther. 2015 Feb;352(2):244-57.

6.Miyazaki Y, Taguchi K, Sou K, Watanabe H, Ishima Y, Miyakawa T, Mitsuya H, Fukagawa M, Otagiri M, Maruyama T. Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia. Mol Pharm. 2014 Nov 3;11(11):4238-48.

7.Anraku M, Tanaka M, Hiraga A, Nagumo K, Imafuku T, Maezaki Y, Iohara D, Uekama K, Watanabe H, Hirayama F, Maruyama T, Otagiri M. Effects of chitosan on oxidative stress and related factors in hemodialysis patients. Carbohydr Polym. 2014 Nov 4;112:152-7.

8.Ogaki S, Taguchi K, Watanabe H, Ishima Y, Otagiri M, Maruyama T. Carbon monoxide-bound red blood cell resuscitation ameliorates hepatic injury induced by massive hemorrhage and red blood cell resuscitation via hepatic cytochrome P450 protection in hemorrhagic shock rats. J Pharm Sci. 2014 Jul;103(7):2199-206.

9.Ishima Y, Fang J, Kragh-Hansen U, Yin H, Liao L, Katayama N, Watanabe H, Kai T, Suenaga A, Maeda H, Otagiri M, Maruyama T. Tuning of poly-S-nitrosated human serum albumin as superior antitumor nanomedicine. J Pharm Sci. 2014 Jul;103(7):2184-8.

10.Nagao S, Taguchi K, Sakai H, Tanaka R, Horinouchi H, Watanabe H, Kobayashi K, Otagiri M, Maruyama T. Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis. Biomaterials. 2014 Aug;35(24):6553-62.

11. Kouno Y, Anraku M, Yamasaki K, Okayama Y, Iohara D, Ishima Y, Maruyama T, Kragh-Hansen U, Hirayama F, Otagiri M. N-acetyl-l-methionine is a superior protectant of human serum albumin against photo-oxidation and reactive oxygen species compared to N-acetyl-L-tryptophan. Biochim Biophys Acta. 2014 Sep;1840(9):2806-12.

12.Hirata K, Saruwatari J, Enoki Y, Iwata K, Urata Y, Aizawa K, Ueda K, Shirouzono T, Imamura M, Moriuchi H, Ishima Y, Kadowaki D, Watanabe H, Hirata S, Maruyama T, Fukunaga E. Possible false-negative results on therapeutic drug monitoring of phenytoin using a particle enhanced turbidimetric inhibition immunoassay in a patient with a high level of IgM. Ther Drug Monit. 2014 Oct;36(5):553-5.

13. Tanaka R, Ishima Y, Maeda H, Kodama A, Nagao S, Watanabe H, Chuang VT, Otagiri M, Maruyama T. Albumin fusion prolongs the antioxidant and anti-inflammatory activities of thioredoxin in mice with acetaminophen-induced hepatitis. Mol Pharm. 2014 Apr 7;11(4):1228-38.

14. Tanaka K, Kurotsu S, Asano T, Yamakawa N, Kobayashi D, Yamashita Y, Yamazaki H, Ishihara T, Watanabe H, Maruyama T, Suzuki H, Mizushima T. Superiority of pulmonary administration of mepenzolate bromide over other routes as treatment for chronic obstructive pulmonary disease. Sci Rep. 2014 Mar 28;4:4510.

15.Sato H, Chuang VT, Yamasaki K, Yamaotsu N, Watanabe H, Nagumo K, Anraku M, Kadowaki D, Ishima Y, Hirono S, Otagiri M, Maruyama T. Differential effects of methoxy group on the interaction of curcuminoids with two major ligand binding sites of human serum albumin. PLoS One. 2014 Feb 3;9(2):e87919.

16.Nagumo K, Tanaka M, Chuang VT, Setoyama H, Watanabe H, Yamada N, Kubota K, Tanaka M, Matsushita K, Yoshida A, Jinnouchi H, Anraku M, Kadowaki D, Ishima Y, Sasaki Y, Otagiri M, Maruyama T. Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases. PLoS One. 2014 Jan 8;9(1):e85216.

17.Watanabe H, Sakaguchi Y, Sugimoto R, Kaneko K, Iwata H, Kotani S, Nakajima M, Ishima Y, Otagiri M, Maruyama T. Human organic anion transporters function as a high-capacity transporter for p-cresyl sulfate, a uremic toxin. Clin Exp Nephrol. 2014 Oct;18(5):814-20

PAGE TOP

2013

1.Ishima Y, Kragh-Hansen U, Maruyama T, Otagiri M. Poly-s-nitrosated albumin as a safe and effective multifunctional antitumor agent: characterization, biochemistry and possible future therapeutic applications. Biomed Res Int. 2013;2013:353892. doi: 10.1155/2013/353892. Epub 2013 Dec 30.

2.Kodama A, Watanabe H, Tanaka R, Kondo M, Chuang VT, Wu Q, Endo M, Ishima Y, Fukagawa M, Otagiri M, Maruyama T. Albumin fusion renders thioredoxin an effective anti-oxidative and anti-inflammatory agent for preventing cisplatin-induced nephrotoxicity. Biochim Biophys Acta. 2014 Mar;1840(3):1152-62. doi: 10.1016/j.bbagen.2013.12.007. Epub 2013 Dec 19.

3.Ishitsuka Y, Fukumoto Y, Kondo Y, Irikura M, Kadowaki D, Narita Y, Hirata S, Moriuchi H, Maruyama T, Hamasaki N, Irie T. Comparative Effects of Phosphoenolpyruvate, a Glycolytic Intermediate, as an Organ Preservation Agent with Glucose and N-Acetylcysteine against Organ Damage during Cold Storage of Mouse Liver and Kidney. ISRN Pharmacol. 2013 Dec 5;2013:375825. doi: 10.1155/2013/375825. eCollection 2013.

4.Taguchi K, Jono H, Kugimiya-Taguchi T, Nagao S, Su Y, Yamasaki K, Mizuguchi M, Maruyama T, Ando Y, Otagiri M. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy. Life Sci. 2013 Dec 18;93(25-26):1017-1022.

5.Watanabe H, Sakaguchi Y, Sugimoto R, Kaneko KI, Iwata H, Kotani S, Nakajima M, Ishima Y, Otagiri M, Maruyama T. Human organic anion transporters function as a high-capacity transporter for p-cresyl sulfate, a uremic toxin. Clin Exp Nephrol. 2013 (in press)

6.Tanaka H, Iwasaki Y, Yamato H, Mori Y, Komaba H, Watanabe H, Maruyama T, Fukagawa M. p-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways. Bone. 2013 Oct;56(2):347-354.

7.Watanabe H. Molecular mechanisms for uremic toxin-induced oxidative tissue damage via a cardiovascular-renal connection. Yakugaku Zasshi. 2013;133(8):889-895.

8.Taguchi K, Ujihira H, Watanabe H, Fujiyama A, Doi M, Takeoka S, Ikeda Y, Handa M, Otagiri M, Maruyama T. Pharmacokinetic study of adenosine diphosphate-encapsulated liposomes coated with fibrinogen γ-chain dodecapeptide as a synthetic platelet substitute in an anticancer drug-induced thrombocytopenia rat model. J Pharm Sci. 2013 Oct;102(10):3852-3829.

9.Nishijima M, Kato H, Fukuhara G, Yang C, Mori T, Maruyama T, Otagiri M, Inoue Y. Photochirogenesis with mutant human serum albumins: enantiodifferentiating photocyclodimerization of 2-anthracenecarboxylate. Chem Commun (Camb). 2013 Aug 28;49(67):7433-7435.

10.Taguchi K, Ujihira H, Ogaki S, Watanabe H, Fujiyama A, Doi M, Okamura Y, Takeoka S, Ikeda Y, Handa M, Otagiri M, Maruyama T. Pharmacokinetic study of the structural components of adenosine diphosphate-encapsulated liposomes coated with fibrinogen γ-chain dodecapeptide as a synthetic platelet substitute. Drug Metab Dispos. 2013 Aug;41(8):1584-1591.

11.Yamasaki K, Chuang VT, Maruyama T, Otagiri M. Albumin-drug interaction and its clinical implication. Biochim Biophys Acta. 2013 Dec;1830(12):5435-5443.

12.Anraku M, Chuang VT, Maruyama T, Otagiri M. Redox properties of serum albumin. Biochim Biophys Acta. 2013 Dec;1830(12):5465-5472.

13.Yamakawa N, Suemasu S, Watanabe H, Tahara K, Tanaka K, Okamoto Y, Ohtsuka M, Maruyama T, Mizushima T. Comparison of pharmacokinetics between loxoprofen and its derivative with lower ulcerogenic activity, fluoro-loxoprofen. Drug Metab Pharmacokinet. 2013;28(2):118-124

14.Tanaka R, Watanabe H, Kodama A, Chuang VT, Ishima Y, Hamasaki K, Tanaka K, Mizushima T, Otagiri M, Maruyama T. Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression. J Pharmacol Exp Ther. 2013 May;345(2):271-283.

15.Ishima Y, Shinagawa T, Yoneshige S, Kragh-Hansen U, Ohya Y, Inomata Y, Kai T, Otagiri M, Maruyama T. UW solution improved with high anti-apoptotic activity by S-nitrosated human serum albumin. Nitric Oxide. 2013 Apr 1;30:36-42.

16.Minomo A, Ishima Y, Chuang VT, Suwa Y, Kragh-Hansen U, Narisoko T, Morioka H, Maruyama T, Otagiri M. Albumin domain II mutant with high bilirubin binding affinity has a great potential as serum bilirubin excretion enhancer for hyperbilirubinemia treatment. Biochim Biophys Acta. 2013 Apr;1830(4):2917-2923.

17.Watanabe H, Miyamoto Y, Honda D, Tanaka H, Wu Q, Endo M, Noguchi T, Kadowaki D, Ishima Y, Kotani S, Nakajima M, Kataoka K, Kim-Mitsuyama S, Tanaka M, Fukagawa M, Otagiri M, Maruyama T. p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int. 2013 Apr;83(4):582-592.

18.Kodama A, Watanabe H, Tanaka R, Tanaka H, Chuang VT, Miyamoto Y, Wu Q, Endo M, Hamasaki K, Ishima Y, Fukagawa M, Otagiri M, Maruyama T. A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy. Kidney Int. 2013 Mar;83(3):446-454.

19.Ogaki S, Taguchi K, Watanabe H, Otagiri M, Maruyama T. Carbon monoxide-bound red blood cells protect red blood cell transfusion-induced hepatic cytochrome p450 impairment in hemorrhagic-shock rats. Drug Metab Dispos. 2013 Jan;41(1):141-8.

20.Watanabe K, Ishima Y, Akaike T, Sawa T, Kuroda T, Ogawa W, Watanabe H, Suenaga A, Kai T, Otagiri M, Maruyama T. S-nitrosated α-1-acid glycoprotein kills drug-resistant bacteria and aids survival in sepsis. FASEB J. 2013 Jan;27(1):391-398.

2012

  1. 1.Ishima Y, Hara M, Kragh-Hansen U, Inoue A, Suenaga A, Kai T, Watanabe H, Otagiri M, Maruyama T. Elucidation of the therapeutic enhancer mechanism of poly-S-nitrosated human serum albumin against multidrug-resistant tumor in animal models. J Control Release. 2012 Nov 28;164(1):1-7. (Cover)
  2. 2.Kadowaki D, Sumikawa S, Arimizu K, Taguchi K, Kitamura K, Ishitsuka Y, Narita Y, Irie T, Chuang VT, Maruyama T, Otagiri M, Hirata S. Effect of acetaminophen on the progression of renal damage in adenine induced renal failure model rats. Life Sci. 2012 Dec 17;91(25-26):1304-8.
  3. 3.Miyamoto Y, Iwao Y, Mera K, Watanabe H, Kadowaki D, Ishima Y, Chuang VT, Sato K, Otagiri M, Maruyama T. A uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropionate induces cell damage to proximal tubular cells via the generation of a radical intermediate. Biochem Pharmacol. 2012 Nov 1;84(9):1207-14.
  4. 4.Yamakawa N, Suemasu S, Watanabe H, Tahara K, Tanaka KI, Okamoto Y, Ohtsuka M, Maruyama T, Mizushima T. Comparison of pharmacokinetics between loxoprofen and its derivative with lower ulcerogenic activity, fluoro-loxoprofen. Drug Metab Pharmacokinet. 2012 Aug 14.
  5. 5.Komori H, Watanabe H, Shuto T, Kodama A, Maeda H, Watanabe K, Kai H, Otagiri M, Maruyama T. α(1)-Acid glycoprotein up-regulates CD163 via TLR4/CD14 protein pathway: possible protection against hemolysis-induced oxidative stress. J Biol Chem. 2012 Aug 31;287(36):30688-700.
  6. 6.Kaneko K, Chuang VT, Ito T, Suenaga A, Watanabe H, Maruyama T, Otagiri M. Arginine 485 of human serum albumin interacts with the benzophenone moiety of ketoprofen in the binding pocket of subdomain III A and III B. Pharmazie. 2012 May;67(5):414-8.
  7. 7.Taguchi K, Chuang VT, Maruyama T, Otagiri M. Pharmaceutical aspects of the recombinant human serum albumin dimer: structural characteristics, biological properties, and medical applications. J Pharm Sci. 2012 Sep;101(9):3033-46.
  8. 8.Watanabe H, Noguchi T, Miyamoto Y, Kadowaki D, Kotani S, Nakajima M, Miyamura S, Ishima Y, Otagiri M, Maruyama T.Interaction between two sulfate-conjugated uremic toxins, p-cresyl sulfate and indoxyl sulfate, during binding with human serum albumin. Drug Metab Dispos. 2012 Jul;40(7):1423-8.
  9. 9.Ishima Y, Hoshino H, Shinagawa T, Watanabe K, Akaike T, Sawa T, Kragh-Hansen U, Kai T, Watanabe H, Maruyama T, Otagiri M. S-guanylation of human serum albumin is a unique posttranslational modification and results in a novel class of antibacterial agents. J Pharm Sci. 2012 Sep;101(9):3222-9.
  10. 10. Iwao Y, Ishima Y, Yamada J, Noguchi T, Kragh-Hansen U, Mera K, Honda D, Suenaga A, Maruyama T, Otagiri M. Quantitative evaluation of the role of cysteine and methionine residues in the antioxidant activity of human serum albumin using recombinant mutants. IUBMB Life. 2012 May;64(5):450-4.
  11. 11. Komori H, Nishi K, Uehara N, Watanabe H, Shuto T, Suenaga A, Maruyama T, Otagiri M. Characterization of hepatic cellular uptake of α1-acid glycoprotein (AGP), part 2: involvement of hemoglobin β-chain on plasma membranes in the uptake of human AGP by liver parenchymal cells. J Pharm Sci. 2012 Apr;101(4):1607-15.
  12. 12. Ishima Y, Chen D, Fang J, Maeda H, Minomo A, Kragh-Hansen U, Kai T, Maruyama T, Otagiri M. S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects. Bioconjug Chem. 2012 Feb 15;23(2):264-71.
  13. 13. Nishi K, Komori H, Kikuchi M, Uehara N, Fukunaga N, Matsumoto K, Watanabe H, Nakajou K, Misumi S, Suenaga A, Maruyama T, Otagiri M. Characterization of the hepatic cellular uptake of α(1) -acid glycoprotein (AGP), part 1: a peptide moiety of human AGP is recognized by the hemoglobin β-chain on mouse liver parenchymal cells. J Pharm Sci. 2012 Apr;101(4):1599-606. 

PAGE TOP

2011

  1. 1.Minomo A, Ishima Y, Kragh-Hansen U, Chuang VT, Uchida M, Taguchi K, Watanabe H, Maruyama T, Morioka H, Otagiri M. Biological characteristics of two lysines on human serum albumin in the high-affinity binding of 4Z,15Z-bilirubin-IXα revealed by phage display. FEBS J. 2011 Nov;278(21):4100-11.
  2. 2.Guo J, Jono H, Kugimiya T, Saito S, Maruyama T, Misumi Y, Hoshii Y, Su Y, Shono M, Ueda M, Obayashi K, Otagiri M, Ando Y. Antioxidative effect of albumin on amyloid fibril formation in transthyretin-related amyloidosis. Amyloid. 2011 Jun;18 Suppl 1:12-3. No abstract available.
  3. 3.Ishima Y, Yoshida F, Kragh-Hansen U, Watanabe K, Katayama N, Nakajou K, Akaike T, Kai T, Maruyama T, Otagiri M. Cellular uptake mechanisms and responses to NO transferred from mono- and poly-S-nitrosated human serum albumin. Free Radic Res. 2011 Oct;45(10):1196-206.
  4. 4.Zhang JS, Kadowaki D, Nonoguchi H, Hirata S, Seo H, Imai T, Suenaga A, Giam Chuang VT, Otagiri M. Toxicodynamic evaluation of a cisplatin-chondroitin sulfate complex using a perfused kidney and human proximal tubular cells. Ren Fail. 2011;33(6):609-14.
  5. 5.Furukawa M, Tanaka R, Chuang VT, Ishima Y, Taguchi K, Watanabe H, Maruyama T, Otagiri M. Human serum albumin-thioredoxin fusion protein with long blood retention property is effective in suppressing lung injury. J Control Release. 2011 Sep 5;154(2):189-95.
  6. 6.Tanaka M, Tokunaga K, Maruyama T, Otagiri M, Tominaga Y, Itoh K, Matsushita K, Komaba H, Fukagawa M Parathyroidectomy markedly reduces oxidative stress in a patient with primary hyperparathyroidism. Ther Apher Dial. 2011 Jun;15 Suppl 1:38-41. doi:
  7. 7.Watanabe H, Miyamoto Y, Otagiri M, Maruyama T. Update on the pharmacokinetics and redox properties of protein-bound uremic toxins. J Pharm Sci. 2011 Sep;100(9):3682-95
  8. 8.Kugimiya T, Jono H, Saito S, Maruyama T, Kadowaki D, Misumi Y, Hoshii Y, Tasaki M, Su Y, Ueda M, Obayashi K, Shono M, Otagiri M, Ando Y. Loss of functional albumin triggers acceleration of transthyretin amyloid fibril formation in familial amyloidotic polyneuropathy. Lab Invest. 2011 Aug;91(8):1219-28
  9. 9.Kaneko K, Chuang VT, Minomo A, Yamasaki K, Bhagavan NV, Maruyama T, Otagiri M. Histidine146 of human serum albumin plays a prominent role at the interface of subdomains IA and IIA in allosteric ligand binding. IUBMB Life. 2011 Apr;63(4):277-85
  10. 10.Anraku M, Takeuchi K, Watanabe H, Kadowaki D, Kitamura K, Tomita K, Kuniyasu A, Suenaga A, Maruyama T, Otagiri M. Quantitative analysis of cysteine-34 on the anitioxidative properties of human serum albumin in hemodialysis patients. J Pharm Sci. 2011 Sep;100(9):3968-76
  11. 11.Taguchi K, Maruyama T, Otagiri M. Pharmacokinetic properties of hemoglobin vesicles as a substitute for red blood cells. Drug Metab Rev. 2011 Aug;43(3):362-73
  12. 12.Tanaka M, Tokunaga K, Komaba H, Itoh K, Matsushita K, Watanabe H, Kadowaki D, Maruyama T, Otagiri M, Fukagawa M. Vitamin d receptor activator reduces oxidative stress in hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial. 2011 Apr;15(2):161-8.
  13. 13.Miyamoto Y, Watanabe H, Otagiri M, Maruyama T. New insight into the redox properties of uremic solute indoxyl sulfate as a pro- and anti-oxidant. Ther Apher Dial. 2011 Apr;15(2):129-31. Review
  14. 14.Mera K, Nagai R, Takeo K, Izumi M, Maruyama T, Otagiri M. An autoantibody against N(ε)-(carboxyethyl)lysine (CEL): Possible involvement in the removal of CEL-modified proteins by macrophages. Biochem Biophys Res Commun. 2011 Apr 8;407(2):420-5.
  15. 15.Nishi K, Ono T, Nakamura T, Fukunaga N, Izumi M, Watanabe H, Suenaga A, Maruyama T, Yamagata Y, Curry S,Otagiri M. Structural Insights into Differences in Drug-binding Selectivity between Two Forms of Human {alpha}1-Acid Glycoprotein Genetic Variants, the A and F1*S Forms. J Biol Chem. 2011 Apr 22;286(16):14427-34.
  16. 16.Miyamoto Y, Watanabe H, Noguchi T, Kotani S, Nakajima M, Kadowaki D, Otagiri M, Maruyama T.Organic anion transporters play an important role in the uptake of p-cresyl sulfate, a uremic toxin, in the kidney.　Nephrol Dial Transplant. 2011 (in press)
  17. 17.Taguchi K, Ogaki S, Watanabe H, Kadowaki D, Sakai H, Kobayashi K, Horinouchi H, Maruyama T, Otagiri M. Fluid Resuscitation with Hemoglobin Vesicles Prevents Escherichia coli Growth via Complement Activation in a Hemorrhagic Shock Rat Model. J Pharmacol Exp Ther. 2011 Apr;337(1):201-8.
PAGE TOP

2010

  1. 1.Anraku M, Michihara A, Yasufuku T, Akasaki K, Tsuchiya D, Nishio H, Maruyama T, Otagiri M, Maezaki Y, Kondo Y, Tomida H. The antioxidative and antilipidemic effects of different molecular weight chitosans in metabolic syndrome model rats. Biol Pharm Bull. 2010;33(12):1994-8.
  2. 2.Taguchi K, Iwao Y, Watanabe H, Kadowaki D, Sakai H, Kobayashi K, Horinouchi H, Maruyama T, Otagiri M. Repeated injection of high doses of hemoglobin-encapsulated liposomes (hemoglobin vesicles) induces accelerated blood clearance in a hemorrhagic shock rat model. Drug Metab Dispos. 2011 Mar;39(3):484-9.
  3. 3.Taguchi K, Urata Y, Anraku M, Watanabe H, Kawai K, Komatsu T, Tsuchida E, Maruyama T, Otagiri M. Superior plasma retention of a cross-linked human serum albumin dimer in nephrotic rats as a new type of plasma expander. Drug Metab Dispos. 2010 Dec;38(12):2124-9.
  4. 4.Taguchi K, Miyasato M, Watanabe H, Sakai H, Tsuchida E, Horinouchi H, Kobayashi K, Maruyama T, Otagiri M. Alteration in the pharmacokinetics of hemoglobin-vesicles in a rat model of chronic liver cirrhosis is associated with Kupffer cell phagocyte activity. J Pharm Sci. 2011 Feb;100(2):775-83.
  5. 5.Taguchi K, Miyasato M, Ujihira H, Watanabe H, Kadowaki D, Sakai H, Tsuchida E, Horinouchi H, Kobayashi K, Maruyama T, Otagiri M. Hepatically-metabolized and -excreted artificial oxygen carrier, hemoglobin vesicles, can be safely used under conditions of hepatic impairment. Toxicol Appl Pharmacol. 2010 Nov 1;248(3):234-41.
  6. 6.Ikuta S, Chuang VT, Ishima Y, Nakajou K, Furukawa M, Watanabe H, Maruyama T, Otagiri M. Albumin fusion of thioredoxin--the production and evaluation of its biological activity for potential therapeutic applications. J Control Release. 2010 Oct 1;147(1):17-23.
  7. 7.Nishi K, Fukunaga N, Ono T, Akuta T, Yumita N, Watanabe H, Kadowaki D, Suenaga A, Maruyama T, Otagiri M. Construction of an expression system for human alpha(1)-acid glycoprotein in E. coli: The roles of oligosaccharide moieties in structural and functional properties. Drug Metab Pharmacokinet. 2010;25(2):200-7.
  8. 8.Ishima Y, Hiroyama S, Kragh-Hansen U, Maruyama T, Sawa T, Akaike T, Kai T, Otagiri M. One-step preparation of S-nitrosated human serum albumin with high biological activities. Nitric Oxide. 2010 Sep 15;23(2):121-7.
  9. 9.Miyamoto Y, Iwao Y, Tasaki Y, Sato K, Ishima Y, Watanabe H, Kadowaki D, Maruyama T, Otagiri M. The uremic solute indoxyl sulfate acts as an antioxidant against superoxide anion radicals under normal-physiological conditions. FEBS Lett. 2010 Jul 2;584(13):2816-20.
  10. 10.Hirata K, Maruyama T, Watanabe H, Maeda H, Nakajou K, Iwao Y, Ishima Y, Katsumi H, Hashida M, Otagiri M. Genetically engineered mannosylated-human serum albumin as a versatile carrier for liver-selective therapeutics. J Control Release. 2010 Jul 1;145(1):9-16.
  11. 11.Matsumoto K, Nishi K, Kikuchi M, Watanabe H, Nakajou K, Komori H, Kadowaki D, Suenaga A, Maruyama T, Otagiri M. Receptor-mediated uptake of human alpha1-acid glycoprotein into liver parenchymal cells in mice. Drug Metab Pharmacokinet. 2010;25(1):101-7.
  12. 12.Katayama N, Nakajou K, Ishima Y, Ikuta S, Yokoe J, Yoshida F, Suenaga A, Maruyama T, Kai T, Otagiri M. Nitrosylated human serum albumin (SNO-HSA) induces apoptosis in tumor cells. Nitric Oxide. 2010 May 15;22(4):259-65.
  13. 13.Mera K, Takeo K, Izumi M, Maruyama T, Nagai R, Otagiri M. Effect of reactive-aldehydes on the modification and dysfunction of human serum albumin. J Pharm Sci. 2010 Mar;99(3):1614-25.
PAGE TOP

2009

  1. 1.Kadowaki D, Anraku M, Tasaki Y, Taguchi K, Shimoishi K, Seo H, Hirata S, Maruyama T, Otagiri M. Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats. Biol Pharm Bull. 2009 Dec;32(12):2041-5.
  2. 2.Chuang VT, Maruyama T, Otagiri M. Updates on contemporary protein binding techniques. Drug Metab Pharmacokinet. 2009;24(4):358-64.
  3. 3.Ishima Y, Kragh-Hansen U, Maruyama T, Otagiri M. Albumin as a nitric oxide-traffic protein: characterization, biochemistry and possible future therapeutic applications. Drug Metab Pharmacokinet. 2009;24(4):308-17.
  4. 4.Taguchi K, Urata Y, Anraku M, Watanabe H, Kadowaki D, Sakai H, Horinouchi H, Kobayashi K, Tsuchida E, Maruyama T, Otagiri M. Hemoglobin vesicles, polyethylene glycol (PEG)ylated liposomes developed as a red blood cell substitute, do not induce the accelerated blood clearance phenomenon in mice. Drug Metab Dispos. 2009 Nov;37(11):2197-203.
  5. 5.Tomida H, Fujii T, Furutani N, Michihara A, Yasufuku T, Akasaki K, Maruyama T, Otagiri M, Gebicki JM, Anraku M. Antioxidant properties of some different molecular weight chitosans. Carbohydr Res. 2009 Sep 8;344(13):1690-6.
  6. 6.Taguchi K, Urata Y, Anraku M, Maruyama T, Watanabe H, Sakai H, Horinouchi H, Kobayashi K, Tsuchida E, Kai T, Otagiri M. Pharmacokinetic study of enclosed hemoglobin and outer lipid component after the administration of hemoglobin vesicles as an artificial oxygen carrier. Drug Metab Dispos. 2009 Jul;37(7):1456-63.
  7. 7.Taguchi K, Maruyama T, Iwao Y, Sakai H, Kobayashi K, Horinouchi H, Tsuchida E, Kai T, Otagiri M. Pharmacokinetics of single and repeated injection of hemoglobin-vesicles in hemorrhagic shock rat model. J Control Release. 2009 Jun 19;136(3):232-9.
  8. 8.Nishi K, Ueno M, Murakami Y, Fukunaga N, Akuta T, Kadowaki D, Watanabe H, Suenaga A, Maruyama T, Otagiri M. A site-directed mutagenesis study of drug-binding selectivity in genetic variants of human alpha(1)-acid glycoprotein. J Pharm Sci. 2009 Nov;98(11):4316-26.
  9. 9.Iwao Y, Hiraike M, Kragh-Hansen U, Kawai K, Suenaga A, Maruyama T, Otagiri M. Altered chain-length and glycosylation modify the pharmacokinetics of human serum albumin. Biochim Biophys Acta. 2009 Apr;1794(4):634-41.
  10. 10.Anraku M, Fujii T, Furutani N, Kadowaki D, Maruyama T, Otagiri M, Gebicki JM, Tomida H. Antioxidant effects of a dietary supplement: reduction of indices of oxidative stress in normal subjects by water-soluble chitosan. Food Chem Toxicol. 2009 Jan;47(1):104-9.
  11. 11. Taguchi K, Maruyama T, Iwao Y, Sakai H, Kobayashi K, Horinouchi H, Tsuchida E, Kai T, Otagiri M. Pharmacokinetics of single and repeated injection of hemoglobin-vesicles in hemorrhagic shock rat model. J Control Release. 2009 Jun 19;136(3):232-9. 42.
  12. 12. Nishi K, Ueno M, Murakami Y, Fukunaga N, Akuta T, Kadowaki D, Watanabe H, Suenaga A, Maruyama T, Otagiri M. A site-directed mutagenesis study of drug-binding selectivity in genetic variants of human alpha(1)-acid glycoprotein. J Pharm Sci. 2009 Nov;98(11):4316-26.
  13. 13. Iwao Y, Hiraike M, Kragh-Hansen U, Kawai K, Suenaga A, Maruyama T, Otagiri M. Altered chain-length and glycosylation modify the pharmacokinetics of human serum albumin. Biochim Biophys Acta. 2009 Apr;1794(4):634-41.
  14. 14. Anraku M, Fujii T, Furutani N, Kadowaki D, Maruyama T, Otagiri M, Gebicki JM, Tomida H. Antioxidant effects of a dietary supplement: reduction of indices of oxidative stress in normal subjects by water-soluble chitosan. Food Chem Toxicol. 2009 Jan;47(1):104-9.
PAGE TOP